Urokinase Market Report 2026

Urokinase Market Overview

• Urokinase market size has reached to $1.81 billion in 2025 • Expected to grow to $2.38 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Rising Cardiovascular Disease Burden Drives Urokinase Market Growth • Market Trend: Strategic Partnerships Revitalize Urokinase Market Through Reintroduction And Innovation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Urokinase Market?

Urokinase is a therapeutic enzyme that acts as a thrombolytic agent to dissolve blood clots. It works by activating plasminogen into plasmin, which then degrades fibrin, the primary protein in blood clots. It is used in clinical settings to treat conditions such as acute myocardial infarction and other blood clotting-related diseases by restoring blood flow and reducing the risk of severe complications from clot formation. The main types of urokinase are urokinase powder and urokinase solution. Urokinase powder refers to the dry, powdered form of the thrombolytic drug urokinase, which is typically reconstituted with sterile water or saline solution before administration, and allows easier storage, transportation, and dosage preparation compared to liquid formulations. The various manufacturing processes include biotechnological methods and traditional extraction. It is used for varying indications such as catheter clearance, coronary artery thrombosis, deep vein thrombosis, and pulmonary embolism. It is provided through many distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for different applications such as hospitals, clinics, and others.

What Is The Urokinase Market Growth Forecast?

The urokinase market size is expected to see strong growth in the next few years. It will grow to $2.38 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in biotechnological manufacturing methods, rising adoption of recombinant urokinase, growth in minimally invasive vascular procedures, increasing awareness of early thrombolytic intervention, expanding healthcare infrastructure in emerging markets. Major trends in the forecast period include increasing use of thrombolytic therapies for acute cardiovascular conditions, rising adoption of recombinant and biotechnologically produced urokinase, growing demand for catheter clearance and minimally invasive procedures, expansion of hospital-based thrombolytic treatment protocols, improved formulations and ready-to-use urokinase solutions.

Global Urokinase Market Segmentation

1) By Type: Urokinase Powder, Urokinase Solution 2) By Manufacturing Process: Biotechnological Methods, Traditional Extraction 3) By Indication: Catheter Clearance, Coronary Artery Thrombosis, Deep Vein Thrombosis, Pulmonary Embolism 4) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By Application: Hospital, Clinics, Other Applications Subsegments: 1) By Urokinase Powder: Pharmaceutical-Grade Urokinase Powder, Research-Grade Urokinase Powder, Recombinant Urokinase Powder 2) By Urokinase Solution: Injectable Urokinase Solution, Infusion Urokinase Solution, Pre-mixed Urokinase Solution

What Is The Driver Of The Urokinase Market?

The growing burden of cardiovascular diseases is expected to propel the growth of the urokinase market going forward. Cardiovascular diseases (CVDs) refer to a range of disorders affecting the heart and blood vessels, including conditions such as heart attacks, strokes, and hypertension. The rising burden of cardiovascular diseases is due to factors such as higher obesity rates caused by a lack of physical activity, unhealthy eating habits, and an aging population. Urokinase contributes to alleviating the increasing impact of cardiovascular diseases by breaking down blood clots that block blood flow, helping prevent heart attacks and strokes, restoring proper circulation, and mitigating further cardiovascular damage. For instance, October 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, in 2023, 919,032 people died from cardiovascular disease. That's the equivalent of 1 in every 3 deaths. Therefore, the growing burden of cardiovascular diseases is driving the growth of the urokinase industry.

Key Players In The Global Urokinase Market

Major companies operating in the urokinase market are Thermo Fisher Scientific Inc., Mochida Pharmaceutical Co. Ltd., Bharat Serums and Vaccines Limited, Taj Pharmaceuticals Ltd., TTK Health Care Limited, Agrata Biotech Limited, Cerbios-Pharma SA, Microbix Biosystems Inc., Midas Pharma GmbH, ImaRx Therapeutics, Health Biotech Limited, Salvavidas Pharmaceutical Pvt. Ltd., BBT Biotech GmbH, Syner-Med (Pharmaceutical Products) Ltd., Echelon Biosciences Inc., Kraeber & Co GmbH, Samarth Life Science Pvt. Ltd., WUHAN HANWEISHI PHARMCHEM CO. LTD., Aetos Pharma, MITS CRITICAL CARE

Global Urokinase Market Trends and Insights

Major companies operating in the urokinase market are reintroducing and commercializing pharmaceutical products for new indications to enhance treatment efficacy, market competitiveness, and patient accessibility. Reintroduction and commercialization of a pharmaceutical product for new indications involve the process of bringing a previously available or discontinued drug back to the market for new disease treatment and implementing strategies to make it available and successful through marketing, distribution, and sales efforts. For instance, in May 2023, MBX Biosciences, a US-based biopharmaceutical company, partnered with Sequel Pharma LLC, a US-based pharmaceutical company, to reintroduce and commercialize kinlytic urokinase. It aims to enhance its presence in the catheter clearance market and improve treatment outcomes for patients. This collaboration highlights the trend of leveraging strategic partnerships to effectively revive and promote pharmaceutical products, ensuring they meet current market needs and regulatory standards.

What Are Latest Mergers And Acquisitions In The Urokinase Market?

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired DICE Therapeutics Inc. for $48 billion. The acquisition aims to bolster Eli Lilly's research and development capabilities in innovative therapies, potentially advancing their portfolio in thrombolytic treatments and related areas, including the development and optimization of therapies that may intersect with urokinase-based treatments. DICE Therapeutics Inc. is a US-based biotechnology company that focuses on discovering and developing novel therapies for autoimmune and inflammatory diseases.

Regional Insights

North America was the largest region in the urokinase market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Urokinase Market?

The urokinase market consists of sales of urokinase thrombolytic agents, urokinase enzymes, and urokinase injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Urokinase Market Report 2026?

The urokinase market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the urokinase industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.